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Managing thyroid dysfunction is simple at first glance, the idea is to bring hormone levels in the euthyroid range, treat
with antithyroid drugs, radio-iodine or surgery if toxic and replace with thyroxine or T3 if hypothyroid. Complexities
arise when there are coexisting conditions that affect the thyroid or are affected by thyroid dysfunction and this review
will deal with the special situations that need care when correcting thyroid hormone levels.Pregnancy
Pregnancy induces several changes in thyroid function. An
early change is the reduction of the available iodide pool
due to an increase of iodine clearance by the kidneys and
the transplacental transfer of iodide and iodothyronine to
the fetus. To avoid iodine deficiency, increase in dietary
iodine intake is recommended for pregnant women
(250 μg/d vs. 150 μg/d in non-pregnant women [1]).
Thyroid related problems are common in pregnancy.
Obvious hypothyroidism can occur in up to 2% pregnan-
cies and subclinical hypothyroidism in up to 3% of preg-
nant women, hyperthyroidism can occur in up to 0.4%
pregnancies [2]. Post partum thyroiditis can be seen in up
to 10%. Comparison with normal prevalence rates can be
difficult because thyroid dysfunction tends to increase
with age, however in one study 1.5% females under 30
were hypothyroid [3], in another study prevalence of pre-
viously undiagnosed thyrotoxicosis was 0.47% [4].
Most thyroid dysfunction is autoimmune in nature and
Graves’ disease accounts for thyrotoxicosis and Hashimo-
to’s thyroiditis for hypothyroidism in most cases.
While de novo thyroid problems are common in preg-
nancy; autoimmune thyroid disease, specially Graves’ dis-
ease, might get better during pregnancy and the disease
can show post partum exacerbation [5,6].* Correspondence: dsabih@yahoo.com
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both are complicated by the fact that:
1. There is an increase in thyroid binding globulin level
in early pregnancy to almost twice the non-pregnant
levels secondary to reduced clearance of TBG by the
liver and an increase in its production under the
influence of estrogen. There is increased total T3 and
T4 levels [7,8]. Free T4 (FT4) and Free T3 (FT3)
levels are not affected by increased serum
thyroglobulin concentrations but caution needs to be
exercised in the interpretation of FT4 levels and
laboratories should establish their own trimester
specific reference range [9]. First and third trimester
FT4 levels are significantly different [10].
2. Human chorionic gonadotrophin (hCG) produced by
the placenta, has a weak thyrotropin (TSH) like
activity and causes a transient increase in FT4
concentration during the first trimester. TSH levels
tend to be low throughout pregnancy but especially
so in the first trimester, so this alone cannot be used
as a marker for thyroid functional status [11]. The
upper normal limits of TSH in the first trimester
have recently been revised to 2.5 mIU/L [12]. In
twins the TSH values are even lower.
The best tests are the combination of TSH and FT4,
TSH being interpreted according to trimester specific
values for the population (Table 1). There are some recom-
mendations that include thyroid peroxidase antibodies
(TPOAb) in the thyroid workup of pregnant women.
It is important to recognize and treat thyroid dysfunc-
tion in pregnancy because of a number of adverse affectsCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Trimester specific levels for TSH (from ref [12])
First Trimester 0.1-2.5 Miu/L
Second Trimester 0.2-3.0 Miu/L
Third Trimester 0.3-3.0 Miu/L
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and fetus (Table 2).
Hypothyroidism in pregnancy
The lab diagnosis of hypothyroidism rests on the dem-
onstration of increased trimester specific TSH levels in
the pregnant woman, the distinction between overt
hypothyroidism (OH) and Subclinical hypothyroidism is
further made depending upon the presence of low or
normal FT4 levels when interpreted in the context of
trimester specific reference range [10].Table 2 Adverse effects of thyroid dysfunction in
pregnancy




























* The fetus needs transplacental supply of thyroid hormones during the first
trimester for early brain development.Women with overt or subclinical hypothyroidism should
be treated with oral thyroxine to normalize the TSH
within the trimester specific reference range. Women with
pre-existing hypothyroidism should undergo frequent
monitoring (monthly till 20 weeks, then again at around
32 weeks) of TSH and the dose of thyroxine adjusted to
maintain this within the trimester specific reference range.
But they must be instructed to immediately increase their
thyroxine dosage by 25% upon missing a period. Some
women will need up to 80% more thyroxine to maintain
their TSH levels within the normal reference range but
fine adjustment can be done at the 6 week mark.
After delivery a previously hypothyroid woman should
go back to her pre-pregnancy dose but this should be
adjusted by getting a TSH done 6 weeks after delivery.
Up to half will need an upward dose adjustment from
the pre-pregnancy level.
Thyrotoxicosis
Up to 1% women may develop thyrotoxicosis in preg-
nancy. Commonest autoimmune cause is Graves’ disease
[13]. Some women might experience transient “gesta-
tional hyperthyroidism” in the first half of pregnancy.
This presents with increased FT4 and suppressed TSH
levels without the presence of serum markers of thyroid
autoimmunity [14]. Gestational hyperthyroidism may be
related to elevated hCG levels and has been associated
with hyperemesis gravidarum. The presence of nodularity
should increase the suspicion of probable T3 toxicosis
and the test protocol should then include T3 levels too.
Gestational hyperthyroidism, once confirmed (absence of
maternal goiter, eye signs, antibodies) should be managed
conservatively, the aim being the treatment of hyperemesis
with fluids and medication to control vomiting. The use of
antithyroid medication is not recommended because the
hormone levels become normal by about 20 weeks of
gestational. In situations where the distinction between
Graves’ disease and Gestational hyperthyroidism cannot be
made, it might be prudent to start low dose antithyroid
therapy, adjusting the dose, or discontinuing these in light
of follow-up TSH levels.
Once it has been decided that the patient needs anti-
thyroid treatment, propylthiouracil (PTU) should be used
in the first trimester; after which treatment should be
switched to Methimazole or carbimazole. Methimazole
or Carbimazole in the first trimester can cause “MMI or
carbimazole embryopathy” [15-18], propylthiouracil is safe
in this period but can be hepatotoxic at any time [19] so
the risks should be explained to the patient. Generally low
initial doses of antithyroid drugs are recommended and
suggested doses are PTU, 50-300 mg/day, Carbimazole
10-15 mg/day, MMI 5-15 mg/day [12]. Beta blockers like
propranolol can be used to control severe symptoms
initially but should be discontinued within 2–6 weeks, long
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ation, fetal bradycardia and a higher rate of spontaneous
abortion.
The goal of treatment is to maintain FT4 levels at or just
above the upper limit of normal range adjusting the dose
after every 2–6 weeks in the light of FT4 assays. A corollary
to this recommendation is that subclinical thyrotoxicosis
needs no treatment. Generally, combination of antithyroid
drugs and thyroxine (block and replacement therapy) is not
recommended.
Cardiovascular disease
No peripheral deiodination of T4 occurs in the heart
muscle and the myocyte relies entirely on circulating T3
for its actions. Thyroid hormone effects include reduction
in systemic vascular resistance, increased resting heart rate,
left ventricular contractility and blood volume, it also
increases erythropoietin production and red cell mass [20].
Thyroid dysfunction has significant cardiac effect. Even
when treated and euthyroid, patients with thyroid dys-
function are more prone to cardiovascular disease [21].
Mild and subclinical thyroid dysfunction is associated with
an increased mortality in patients with cardiovascular dis-
ease [22-24].
Thyrotoxicosis
Many features of thyrotoxicosis derive from the effect of
excess thyroid hormones on the heart and include palpi-
tation, tachycardia, exercise intolerance (from an inabi-
lity to further increase heart rate), wide pulse pressure
and sometimes atrial fibrillation. Cardiac output might
increase by 50-300%.
Angina, with ECG changes of ischemia, can be pro-
voked by thyrotoxicosis, even in the presence of normal
coronary arteries, this is presumed to be due to coronary
artery spasm or a prothrombotic state induced by thyro-
toxicosis in young patients [25]. In older patients with
preexisting or suspected cardiac ischemia, this might re-
flect an increased oxygen demand by the myocardium.
[26,27]. Treating thyrotoxicosis with available options
improves cardiac symptoms.
Atrial fibrillation
Almost all patients with thyrotoxicosis have sinus tachy-
cardia but the most significant tachyarrythmia is atrial
fibrillation that may be present in 2-20% of patients [28].
Although thyrotoxicosis is responsible for only 1% of all
atrial fibrillations, thyroid testing in all patients with
new onset AF is justified because of the ability to restore
the rhythm to normal with reversion of the patient to
euthyroid state.
The ventricular rate slows when patients of thyrotoxi-
cosis induced atrial fibrillation are treated with β-blockers.The thyroid status should be corrected with antithyroid
drugs or radio-iodine.
Heart failure
Thyrotoxic patients may exhibit features of heart failure. It
is a precipitating factor and tachycardia and atrial fibrilla-
tion may cause rate limited left ventricular dysfunction
and failure [29]. The definitive treatment of choice of the
thyrotoxicosis in these patients is radioiodine [30,31].
Hypothyroidism
Just like thyrotoxicosis, the cardiovascular manifestations of
hypothyroidism are prominent. These include bradycardia,
mild hypertension, narrow pulse pressure, cold extremities,
increased systemic vascular resistance, decreased cardiac
contractility and output, accelerated atherosclerosis and
coronary artery disease, cold intolerance and fatigue [20].
ECG changes include a prolongation of the QT interval
that predisposes to ventricular irritability [32]. There is
prolongation of the isovolumic diastolic relaxation. Many
patients can develop pericardial or pleural effusion.
Managing hypothyroidism in the presence of cardiac
disease in young adults is easy and a full replacement dose
can be initiated. Some cases of chest pain, particularly the
elderly will remain challenging and thyroid replacement
therapy might exacerbate angina [33]. Treatment should
be started with a very low dose (25–50 μg/day) with a very
slow increase (every 6–8 weeks); this will usually improve
cardiac function [34].
Low T3 syndrome
Up to a third of patients with heart failure have low T3
levels with normal T4 and TSH levels [35]. In this set-
ting a reduced T3 is a strong predictor of mortality.
There might be a place for physiological T3 replacement
in such cases [29]. Placebo controlled trials suggest be-
nefits of short term T3 replacement in neuroendocrine
profile, stroke volume and cardiac output without in-
crease in cardiac workload [36].
Drugs
Amiodarone
Amiodarone is a popular drug used for cardiac rhythm
disturbance (both atrial and ventricular). It inhibits per-
ipheral deiodination of T4 and decreases T3 concentration
in the serum. It has a very high iodine content and can
cause either hypothyroidism (5-25% of treated patients) or
thyrotoxicosis (20-10% of treated patients) [37].
Hypothyroidism
Patients on amiodarone therapy should be regularly
tested for thyroid function by TSH and replacement
therapy should be started if the TSH levels increase.
Amiodarone is not discontinued and the replacement
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and a mid range or high normal T4 level would suggest
subclinical hypothyroidism and should be treated with
thyroxine replacement therapy [38].Thyrotoxicosis
Two types of amiodarone induced thyrotoxicosis have
been described, type 1 occurring in those with pre-existing
thyroid disease and goiter, and type 2 occurring in normal
sized thyroids with no previous history of thyroid disease.
Type 2 thyrotoxicosis is a destructive thyroiditis and in
many cases the patient passes from a thyrotoxic state to a
hypothyroid state in a few months. Type 2 thyrotoxicosis
can occur suddenly at any time during treatment and thy-
roid function tests should be done at the slightest suspi-
cion of a possible thyroid dysfunction.
Treatment of amiodarone induced thyrotoxicosis is diffi-
cult and some times the distinction of type 1 from type 2
is difficult or cannot be made. No consensus exists on the
most effective and appropriate regimen. Discontinuation
of amiodarone rarely helps, perhaps because the terminal
half life is very long (about 4 months) [38]. β- blockers
and steroids (unless the patient is a diabetic) have been
used. After cessation of amiodarone, high doses of thio-
urea derivatives like carbimazole have been suggested but
no consistent benefits have been demonstrated. In patients
with pre-existing Graves’ disease or toxic multinodular
goiter, radioiodine can be given (type 1), but it is not useful
in type 2 amiodarone thyrotoxicosis.
In some patients, amiodarone cannot be discontinued
due to risks of exacerbation of thyrotoxicosis and serious
ventricular arrhythmias upon cessation [39,40] and other
reasons. It might be safer in these to continue with amio-
darone and treat thyrotoxicosis aggressively although this
tends to reduce the chances of a successful outcome [38].
Thyroidectomy is an option in such a situation [41] and
has been associated with improvement in cardiac as well
as thyroid function. Thyroidectomy has been done under
local anesthesia in patients deemed unfit for general
anesthesia [42]. Plasmapheresis has occasionally been
used but with inconsistent success [43]. Table 3 describesTable 3 Treatment of Amiodarone induced thyrotoxicosis (fro
Type 1 thyrotoxicosis




Amodiarone cannot be discontinued Antithyroid drugs
Radio-iodine
Surgerythe therapeutic options in different types of amiodarone
induced toxicosis.Lithium
Lithium is a psychoactive drug and is used in depression.
It is concentrated by the thyroid and impairs thyroidal
iodine uptake, it also inhibits iodotyrosine coupling and
inhibits thyroid hormone secretion [44]. It leads to
hypothyroidism in 20% and goiter in up to 40% patients;
[45]. Rarely it may cause thyrotoxicosis due to thyroiditis
or Graves’ disease [46]. Hypothyriodism should be trea-
ted by thyroxine replacement and lithium therapy should
be continued. Similarly, thyrotoxicosis should be treated
with the available therapeutic options without discon-
tinuing lithium.Interferon
Interferon related hypothyroidism was first reported in
1985 [47]. These patients probably have a genetic predis-
position to autoimmune thyroid disease [48]. The preva-
lence of thyroid disease in patients treated with interferon
varies from 1 to 35% in different reports [49,50]. This
might reflect different methodologies used to diagnose thy-
roid disease or variation in individual susceptibility to thy-
roid disease with interferon treatment. It has also been
argued that viral infection, specially by HCV and to a lesser
extent hepatitis B may predispose to the development of
thyroid autoimmune disease [51], but this has not been
conclusively demonstrated [52]. The commonest thyroid
finding in patients treated with interferon is the presence
of thyroid related antibodies with normal thyroid function;
however, thyroiditis, Graves’ disease and hypothyroidism
can all occur, sometimes in the same patient, destructive
thyroiditis and thyrotoxicosis are additional problems se-
condary to inflammation of the thyroid [53-55].
Discontinuation of interferon is rarely indicated but
may become necessary in severe destructive thyroiditis
and Graves’ disease.
Patients who become hypothyroid during interferon
therapy should have replacement therapy. Their TSH
levels should continue to be monitored after completingm ref [38])
Type 2 thyrotoxicosis
y Withdrawal will suffice in many cases
g four times a day Steroids may needed for up to 3 months
g twice a day
Surgery
Plasmapheresis
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discontinuing interferon [56].
Those who develop thyroiditis can be treated with
steroids.
Destructive thyrotoxicosis may be treated with β - block-
ers and steroids can be added if symptoms are uncon-
trolled; interferon may need to be withdrawn, although this
probably does not influence the natural history of the
disease [54].
Those with mild Grave’s disease, should have continued
interferon therapy with concomitant low dose antithyroid
medication. Severe Graves’ disease is unlikely to resolve
needing very high doses of antithyroid drugs raising con-
cerns about their intrinsic hepatotoxicity. Interferon might
need to be discontinued, awaiting effect of definitive the-
rapy with radio iodine or surgery; after which interferon
may be restarted.
A case of panhypopituitarism has been reported [57].
Such cases need to be treated with steroids preceding thy-
roxine replacement (see section on panhypopituitarism).
Diabetes
Many studies have demonstrated a higher prevalence of
thyroid disease in diabetics (13.4%), that have been as high
as 31.4% for female type-1 diabetes [58]. The same paper
suggests that diabetics be screened annually for thyroid
function. The majority have hypothyroidism (Subclinical
50%, overt 40%), while thyrotoxicosis and thyroiditis are
less common [24]. Common susceptibility genes have
been identified that may offer insight into the higher asso-
ciation of both conditions.
Thyrotoxicosis promotes hyperglycemia. There is increased
degradation of insulin and the release of biologically in-
active insulin precursors [59]. There is increased glucose
absorption from the intestine [60] and increased hepatic
glucose output. There is also increased lipolysis and an in-
crease in free fatty acids that stimulate hepatic gloconeo-
genesis. In short, there is worsening of glycemic control in
diabetics and in some, thyrotoxicosis can be the cause of
diabetic ketoacidosis [61]. While managing thyrotoxicosis
the concurrent effects on blood glucose levels should be
kept in mind and the hypoglycemic agents or insulin doses
optimized, as the need for these reduces with better thy-
roid control.
Hypothyroidism causes reduced rates of glucose pro-
duction by the liver, leading to decreased insulin require-
ment. Recurrent hypoglycemic episodes can be the first
sign of early hypothyroidism in a known diabetic patient
[62]. Patients with subclinical hypothyroidism and dia-
betes are more prone to nephropathy and retinopathy,
favouring the screening of diabetics for thyroid status.
Metformin has been implicated in reducing TSH levels
in a small group of patients. This is an isolated effect that is
not associated with any changes in FT3 or FT4 levels [63].The goal of thyroid replacement in these patients is to
achieve a euthyroid status with a TSH of between 0.3
and 3.0 mIU/ml [64].
Asthma
Thyrotoxicosis
An association between worsening of asthma and thyro-
toxicosis has been known for several decades [65,66]. Des-
pite this known association the routine use of thyroid
function tests in all asthmatics has not been recommended
[67] but there may be a place for thyroid investigation in
persons with worsening asthma. A euthyroid status has a
positive effect on asthma control [68]. In one series all
asthmatic patients developed more serious symptoms as
their thyrotoxicosis became more obvious [69], all
improved when they became euthyroid. Therapy of asthma
in these cases becomes difficult because the thyrotoxic
state induces and aggravates the symptoms associated with
β agonist therapy, and the anti tachycardia treatment of
thyrotoxic symptoms with nonspecific β blockers exacer-
bates asthma. 131I has been given for early radical treat-
ment of thyrotoxicosis with good results [70].
Hypothyroidism
Hypothyroidism improves coexisting asthma. Correction
of hypothyroidism causes worsening of symptoms and dif-
ficulties in controlling asthma [71]. There is blunting of
response to bronchodilator therapy with an inverse rela-
tionship between levels of thyroid function and airway
beta adrenergic responsiveness [72]. Caution must be used
when correcting hypothyroidism in asthmatics because of
the risk of exacerbating asthma.
Addison’s disease
Increased TSH levels, with normal or reduced T4 levels are
often found [73]. Clinical symptoms of tiredness and an
elevated TSH with low T4 will prompt a diagnosis of
hypothyroidism and prescription of thyroxine as repla-
cement therapy. Thyroxine replacement alone in these
patients is dangerous and may precipitate an adrenal crisis
[74,75]. Corticosteroid therapy will often correct the thyroid
biochemical imbalance too [76]. If thyroxine replacement is
deemed necessary it should follow steroid replacement.
Screening all patients of hypothyroidism for adrenal de-
ficiency is not recommended [77], but those patients who
are suspected to be hypothyroid because of raised TSH
and get worse after thyroxine therapy should be reevalu-
ated clinically as well as biochemically for a possible coex-
isting adrenal insufficiency.
Hypopituitarism (secondary hypothyroidism)
Given the relationship between the pituitary and target
organ hormones, pituitary hormones are good indicators
of target organ function and in a converse manner target
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A raised TSH suggests impaired thyroid function, a low
TSH increased thyroid function; a low T4 levels along with
normal or low TSH suggest reduced pituitary function.
The patient may be asymptomatic or suffer an acute
collapse.
Symptoms vary according to the predominant hormone
deficiency and the rapidity of onset [78]. Hypothyroidism
was the second commonest presentation following hypo-
gonadism in one series [79].
Symptoms are usually similar to those of primary target
organ deficiency. Symptoms of thyrotropin deficiency are
the same as primary hypothyroidism. T4 is low but TSH
does not show the expected increase that one expects in
primary hypothyroidism and might be low or in the nor-
mal range. Failure of increase in TSH following thyrotopin
releasing hormone would be confirmatory but is rarely
needed to make the correct diagnosis.
The goal of treatment is hormone replacement but an ex-
tremely important caveat is to ensure that either the glu-
cocorticoid secretion is normal or to precede thyroxine
replacement by glucocorticoid therapy. This will avoid an
adrenal crisis as the metabolism of glucocorticoids increases
under the influence of thyroxine.
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